Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00540423 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Idiopathic Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Idiopathic

Interventions

DRUG: SB-497115-GR 12.5mg
DRUG: SB-497115-GR 25mg
DRUG: SB-497115-GR 12.5mg matching placebo
DRUG: SB-497115-GR 50 mg

Sponsor

GlaxoSmithKline